Advances of Iron and Ferroptosis in Diabetic Kidney Disease DOI Creative Commons

Jiayi Chu,

Kewu Wang,

Lulu Lu

et al.

Kidney International Reports, Journal Year: 2024, Volume and Issue: 9(7), P. 1972 - 1985

Published: April 3, 2024

Diabetes mellitus presents a significant threat to human health because it disrupts energy metabolism and gives rise various complications, including diabetic kidney disease (DKD). Metabolic adaptations occurring in the response diabetes contribute pathogenesis of DKD. Iron ferroptosis, recently defined form cell death resulting from iron-dependent excessive accumulation lipid peroxides, have emerged as crucial players progression In this comprehensive review, we highlight profound impact adaptive maladaptive responses regulating iron on damage diabetes. We summarize current understanding homeostasis ferroptosis Finally, propose that precise manipulation may serve potential strategies for management

Language: Английский

Protein-bound uremic toxins as therapeutic targets for cardiovascular, kidney, and metabolic disorders DOI Creative Commons
Shihan Zhang, Shasha Tang, Yalei Liu

et al.

Frontiers in Endocrinology, Journal Year: 2025, Volume and Issue: 16

Published: Jan. 27, 2025

Cardiovascular-kidney-metabolic (CKM) syndrome is a systemic clinical condition characterized by pathological and physiological interactions among metabolic abnormalities, chronic kidney disease, cardiovascular diseases, leading to multi-organ dysfunction higher incidence of endpoints. Traditional approaches managing CKM risk are inadequate in these patients, necessitating strategies targeting specific factors. Increasing evidence suggests that addressing uremic toxins and/or pathways induced may reduce treat the disease. This review explores heart, kidney, context underscores significant role as potential therapeutic targets pathophysiology diseases. Strategies aimed at regulating offer avenues for reversing syndrome, providing new insights its diagnosis treatment.

Language: Английский

Citations

1
New insights in the treatment of DKD: recent advances and future prospects DOI Creative Commons

Meimei Zhao,

Yongtong Cao, Liang Ma

et al.

BMC Nephrology, Journal Year: 2025, Volume and Issue: 26(1)

Published: Feb. 11, 2025

Diabetic kidney disease (DKD) represents the predominant and severe microvascular complication associated with diabetes, frequently culminating in End-Stage Kidney Disease (ESKD). The escalating prevalence of diabetes has correspondingly led to a rise DKD incidence, imposing significant challenges on both individuals society. etiology is multifaceted remains devoid definitive therapeutic interventions. This article examines pharmacological actions mechanisms different drugs used for prevention treatment that are currently clinical use or undergoing development. goal offer insights early intervention based combinations potentially slow progression.

Language: Английский

Citations

1
Targeting HMGB1: A Potential Therapeutic Strategy for Chronic Kidney Disease DOI Creative Commons
Tongtong Liu, Qian Li, Jin Qi

et al.

International Journal of Biological Sciences, Journal Year: 2023, Volume and Issue: 19(15), P. 5020 - 5035

Published: Jan. 1, 2023

High-mobility group protein box 1 (HMGB1) is a member of highly conserved high-mobility present in all cell types.HMGB1 plays multiple roles both inside and outside the cell, depending on its subcellular localization, context, post-translational modifications.HMGB1 also associated with progression various diseases.Particularly, HMGB1 critical role CKD prognosis.HMGB1 participates key events by activating downstream signals, including renal inflammation, onset persistent fibrosis, aging, AKI-to-CKD transition, important cardiovascular complications.More importantly, distinct chronic pathophysiology kidney disease, which differs from that acute lesions.This review describes regulatory homeostasis summarizes how affects prognosis.Finally, some promising therapeutic strategies for targeted inhibition improving are summarized.Although application as target faces challenges, more in-depth understanding intracellular extracellular mechanisms underly occurrence might render an attractive CKD.

Language: Английский

Citations

19
Critical role of FGF21 in diabetic kidney disease: from energy metabolism to innate immunity DOI Creative Commons

Yingnan Liang,

Qi Chen, Yue Chang

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Jan. 19, 2024

Diabetic kidney disease (DKD) stands as the predominant cause of chronic (CKD) on a global scale, with its incidence witnessing consistent annual rise, thereby imposing substantial burden public health. The pathogenesis DKD is primarily rooted in metabolic disorders and inflammation. Recent years have seen surge studies highlighting regulatory impact energy metabolism innate immunity, forging significant area research interest. Within this context, fibroblast growth factor 21 (FGF21), recognized an regulator, assumes pivotal role. Beyond role maintaining glucose lipid homeostasis, FGF21 exerts influence concurrently inhibiting inflammation fibrosis. Serving nexus between has evolved into therapeutic target for diabetes, nonalcoholic steatohepatitis, cardiovascular diseases. While relationship garnered increased attention recent studies, comprehensive exploration association yet to be systematically addressed. This paper seeks fill gap by summarizing mechanisms through which operates DKD, encompassing facets immunity. Additionally, we aim assess diagnostic prognostic value explore potential treatment modality condition.

Language: Английский

Citations

7
Narrative Review of Immunomodulatory and Anti-inflammatory Effects of Sodium-Glucose Cotransporter 2 Inhibitors: Unveiling Novel Therapeutic Frontiers DOI Creative Commons
Sul A Lee, Leonardo V. Riella

Kidney International Reports, Journal Year: 2024, Volume and Issue: 9(6), P. 1601 - 1613

Published: March 1, 2024

Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) have evolved from their initial role as anti-diabetic drugs to garner recognition for remarkable cardio-protective and reno-protective attributes. They become a crucial component of therapeutic guidelines congestive heart failure proteinuric chronic kidney disease. These benefits extend beyond glycemic control, improvements in cardiovascular renal outcomes occur swiftly. Recent studies unveiled the immunomodulatory properties SGLT2 inhibitors, shedding light on potential influence immune system inflammation. This comprehensive review explores current state knowledge regarding impact inflammation, focusing preclinical clinical evidence. The delves into anti-inflammatory immune-modulating effects, offering insights implications exploring emerging research areas related prospective impact.

Language: Английский

Citations

7
Iridoids modulate inflammation in diabetic kidney disease: A review DOI

Tongyi Zhou,

Na Tian,

Liu Li

et al.

Journal of Integrative Medicine, Journal Year: 2024, Volume and Issue: 22(3), P. 210 - 222

Published: March 28, 2024

Language: Английский

Citations

6
The mechanisms underlying Chinese medicines to treat inflammation in diabetic kidney disease DOI
Leipengyun Deng,

Chunru Shi,

Run Li

et al.

Journal of Ethnopharmacology, Journal Year: 2024, Volume and Issue: 333, P. 118424 - 118424

Published: June 4, 2024

Language: Английский

Citations

6
Association of the dietary inflammation index DII with the prevalence of chronic kidney disease in patients with hypertension DOI Creative Commons

Xin Lü,

Shuang Zhou, Shujun Liu

et al.

Renal Failure, Journal Year: 2024, Volume and Issue: 46(2)

Published: July 5, 2024

Background and objective Chronic kidney disease (CKD) is a global health concern that frequently associated with hypertension. Inflammation an important factor in the development of both illnesses. The Dietary Index (DII) has evolved as way to measure how much diet can cause inflammation, which may impact CKD, especially hypertensive persons. study's goal investigate link between DII occurrence CKD individuals.

Language: Английский

Citations

6
Causal relationship between 731 immune cells and the risk of diabetic nephropathy: a two‑sample bidirectional Mendelian randomization study DOI Creative Commons
Siyuan Song,

Yuqing Sun,

Jiangyi Yu

et al.

Renal Failure, Journal Year: 2024, Volume and Issue: 46(2)

Published: Aug. 1, 2024

Previous observational studies have indicated associations between various immune cells and diabetic nephropathy (DN). However, the causality remains unclear. We aimed to further evaluate causal association DN using bidirectional two-sample Mendelian randomization (MR) analysis.

Language: Английский

Citations

6
Novel Aspects of the Immune Response Involved in the Peritoneal Damage in Chronic Kidney Disease Patients under Dialysis DOI Open Access
Flavia Trionfetti, Vanessa Marchant, Guadalupe Tirma González-Mateo

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(6), P. 5763 - 5763

Published: March 17, 2023

Chronic kidney disease (CKD) incidence is growing worldwide, with a significant percentage of CKD patients reaching end-stage renal (ESRD) and requiring replacement therapies (KRT). Peritoneal dialysis (PD) convenient KRT presenting benefices as home therapy. In PD patients, the peritoneum chronically exposed to fluids containing supraphysiologic concentrations glucose or other osmotic agents, leading activation cellular molecular processes damage, including inflammation fibrosis. Importantly, peritonitis episodes enhance status accelerate peritoneal injury. Here, we review role immune cells in damage membrane (PM) by repeated exposure during well bacterial viral infections. We also discuss anti-inflammatory properties current clinical treatments their potential effect on preserving PM integrity. Finally, given importance coronavirus 2019 (COVID-19) disease, analyze here implications this KRT.

Language: Английский

Citations

16